Actinogen Medical Future Growth

Future criteria checks 2/6

Actinogen Medical's earnings are forecast to decline at 22.1% per annum while its annual revenue is expected to grow at 20% per year. EPS is expected to decline by 0.01% per annum.

Key information

-22.1%

Earnings growth rate

-0.009%

EPS growth rate

Biotechs earnings growth	15.3%
Revenue growth rate	20.0%
Future return on equity	n/a
Analyst coverage	Low
Last updated	31 Oct 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

CHIA:ACW - Analysts future estimates and past financials data (AUD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2026	14	-20	-13	N/A	1
6/30/2025	7	-12	-9	N/A	1
6/30/2024	10	-13	-17	-17	N/A
3/31/2024	7	-14	-15	-15	N/A
12/31/2023	5	-15	-13	-13	N/A
9/30/2023	5	-13	-11	-11	N/A
6/30/2023	5	-11	-9	-9	N/A
3/31/2023	5	-11	-9	-9	N/A
12/31/2022	5	-11	-9	-9	N/A
9/30/2022	4	-10	-9	-9	N/A
6/30/2022	4	-9	-10	-10	N/A
3/31/2022	3	-8	-8	-8	N/A
12/31/2021	2	-7	-6	-6	N/A
9/30/2021	2	-6	-4	-4	N/A
6/30/2021	2	-4	-2	-2	N/A
3/31/2021	2	-4	-2	-2	N/A
12/31/2020	3	-4	-2	-2	N/A
9/30/2020	3	-4	-3	-3	N/A
6/30/2020	4	-5	-3	-3	N/A
3/31/2020	5	-6	-5	-5	N/A
12/31/2019	6	-7	-7	-7	N/A
9/30/2019	5	-8	-9	-9	N/A
6/30/2019	5	-10	-10	-10	N/A
3/31/2019	4	-10	-10	-10	N/A
12/31/2018	3	-10	-9	-9	N/A
9/30/2018	3	-8	-8	-8	N/A
6/30/2018	3	-6	-8	-8	N/A
3/31/2018	2	-6	N/A	-6	N/A
12/31/2017	2	-5	N/A	-4	N/A
9/30/2017	1	-4	N/A	-3	N/A
6/30/2017	1	-3	N/A	-1	N/A
3/31/2017	2	-4	N/A	-2	N/A
12/31/2016	3	-4	N/A	-2	N/A
9/30/2016	3	-4	N/A	-4	N/A
6/30/2016	4	-4	N/A	-5	N/A
3/31/2016	3	-5	N/A	-5	N/A
12/31/2015	1	-5	N/A	-5	N/A
9/30/2015	1	-5	N/A	-4	N/A
6/30/2015	0	-5	N/A	-4	N/A
3/31/2015	0	-3	N/A	-2	N/A
12/31/2014	0	-2	N/A	-1	N/A
9/30/2014	0	-1	N/A	-1	N/A
6/30/2014	0	0	N/A	0	N/A
3/31/2014	0	0	N/A	0	N/A
12/31/2013	0	0	N/A	0	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ACW is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ACW is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ACW is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ACW's revenue (20% per year) is forecast to grow faster than the Australian market (5.7% per year).

High Growth Revenue: ACW's revenue (20% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ACW's Return on Equity is forecast to be high in 3 years time

Actinogen Medical Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Recent updates

Actinogen Medical Appoints Andrew Udell as Chief Commercial Officer

Actinogen Medical Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million.

Actinogen Medical Limited, Annual General Meeting, Nov 14, 2024

New major risk - Revenue and earnings growth

Actinogen Medical Limited Announces Further Positive Results on Depression in the XanCIDD Phase 2A Trial

Actinogen Medical Limited as Announces Achievement of Clinically and Statically Significant Superiority of Xanamem over Placebo on Depression in Xanacidd Phase 2A Trial

New minor risk - Market cap size

Actinogen Medical Limited Announces the Peer-Reviewed Publication of its Phase 2a Biomarker

New major risk - Revenue and earnings growth

Actinogen Medical Limited has filed a Follow-on Equity Offering in the amount of AUD 5 million.

Actinogen Medical Limited Announces First Patient Treated in XanaMIA Phase 2b Alzheimer's Disease Trial

Actinogen Medical Limited Announces Enrolment in the XanaCIDD Phase 2A Proof-Of-Concept Trial

Actinogen Medical Limited Announces CFO Changes

AActinogen Medical Limited to Present Progress on Phase 2 Trials At the Bio Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease Conference, Boston

Actinogen Medical Limited Announces Optimization of XanaMIA Phase 2b Trial in Patients with Mild-to-Moderate Alzheimer's Disease to Reduce Cost and Time to Initial Results

New minor risk - Shareholder dilution

Actinogen Medical Limited, Annual General Meeting, Nov 08, 2023

New minor risk - Financial data availability

New major risk - Financial position

Actinogen Medical Limited to Present Progress on Cognitive Impairment in Depression and Alzheimer's Disease Phase 2 Trials at the BIO International Convention

Actinogen Medical Limited Announces Executive Changes

Actinogen Medical Ltd Announces Receipt of Agreement from US Food and Drug Administration Agrees to Six-Month Phase 2b Alzheimers Disease Trial

Actinogen Medical Limited Announces First Patient Treated in Depression and Cognitive Impairment Phase 2 Clinical Trial

Actinogen Medical Limited Announces First Patient Treated in XanaCIDD Phase 2 Depression Trial

MD, CEO & Director recently bought AU$94k worth of stock

Actinogen Medical Limited Announces Positive Alzheimers Disease Clinical Results

Actinogen Medical Limited, Annual General Meeting, Nov 16, 2022

Actinogen Medical Limited Announces Phase 2 Trials in Alzheimer's Disease and Depression

Actinogen Medical Limited Announces Phase 2 Trial Designs for AD & MDD

MD, CEO & Director recently bought AU$128k worth of stock

Actinogen Medical Limited Announces Positive XanaMIA Results for Xanamem

Actinogen Medical Limited Announces Executive Changes

Actinogen Medical Expects Top-Line Results for the XanaMIA Part A Trial to Be Available in April 1

Actinogen Medical Announces Enrolment Reach in the XanaMIA Part A Trial of 105 Participants

Actinogen Medical Limited Completes Global Patent Family Grant

Actinogen Medical Limited Announces First Patient Enrolled in XanaMIA Trial

Actinogen Receives Positive Pre-IND FDA Advice for FXS

Actinogen Medical Receives Ethics Committee Approval for XanaMIA study

Actinogen Medical Limited Appoints Steven Gourlay as CEO

Actinogen Medical Limited Announces Executive Changes

Actinogen Medical Wins FDA Actinogen's Drug Xanamem Rare Paediatric Disease Designation for the Treatment of Fragile X Syndrome

Actinogen Medical Limited Announces Two New Clinical Trials

Actinogen Medical Limited Appoints Jeff Carter as Chief Financial Officer

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies